ReviewJournal of oral and maxillofacial pathology : JOMFP
Photobiomodulation therapy: Ushering in a new era in personalized supportive cancer care.
Review in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiotherapy-Associated Pain in Head and Neck Cancer: From Clinical Burden to Neuroimmune Modulator.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human body can utilize light for a broad range of pathophysiological responses, such as circadian rhythm, Vitamin D metabolism, and vision, among others. The therapeutic use of light has spanned many ancient health practices. Recent advances in using low-dose light therapy, termed photobiomodulation (PBM), have made tremendous progress in unravelling precise biological mechanisms and clinical dosimetry, enabling this treatment modality's clinical safety and effectiveness. The evidence for PBM has received its strongest endorsement via recent systematic reviews and meta-analyses recommending its routine use to address various acute and chronic side effects associated with cancer treatment. Carefully done studies have noted unequivocal evidence demonstrating its effectiveness in managing oral mucositis in patients undergoing radiotherapy for head and neck cancer, chemotherapy, or hematopoietic stem cell transplantation. This brief narrative review will explore the therapeutic benefits of PBM therapy, supported by recent research findings, to provide a comprehensive understanding of its potential in clinical settings. Additionally, the review will highlight our current understanding of molecular mechanisms underlying PBM and the importance of novel harmonized dosing that enables its optimal clinical implementation and utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.